Profound Medical (TSE:PRN) has released an update.
Profound Medical Corp., known for its incision-free therapies for tissue ablation, will be engaging in a fireside chat at the Barclays 26th Annual Global Healthcare Conference. This live event will take place on March 13, 2024, and will also be accessible via the Company’s website. In addition to its MRI-based TULSA-PRO® for prostate treatment, Profound is expanding its portfolio with the Sonalleve® therapeutic platform for conditions like uterine fibroids and bone metastases pain.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
